Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Company Deals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Fineline Cube Apr 13, 2026
Company Deals Drug

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

Fineline Cube Apr 13, 2026
Company Drug

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Fineline Cube Apr 13, 2026
Company Deals

Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries

Fineline Cube Feb 26, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...

Policy / Regulatory

Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits

Fineline Cube Feb 26, 2024

The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...

Company Drug

GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma

Fineline Cube Feb 26, 2024

GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...

Company Drug

Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC

Fineline Cube Feb 26, 2024

South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...

Company Drug

Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China

Fineline Cube Feb 26, 2024

The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...

Company Deals

Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Drug

Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development

Fineline Cube Feb 23, 2024

Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...

Company Drug

Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio

Fineline Cube Feb 23, 2024

Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Adjuvant Therapy Clinical Study of Adebrelimab in NSCLC

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval...

Company Drug

BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy

Fineline Cube Feb 23, 2024

BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120...

Company Drug

Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study

Fineline Cube Feb 23, 2024

Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...

Company Drug

Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies

Fineline Cube Feb 23, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Company Drug

Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval

Fineline Cube Feb 23, 2024

Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...

Company Drug

AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval

Fineline Cube Feb 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...

Company Drug

Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis

Fineline Cube Feb 22, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...

Company Drug

FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment

Fineline Cube Feb 22, 2024

The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...

Company

AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael

Fineline Cube Feb 22, 2024

AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has...

Company Deals

Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal

Fineline Cube Feb 22, 2024

China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...

Posts pagination

1 … 382 383 384 … 649

Recent updates

  • AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data
  • RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma
  • Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo
  • AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease
  • IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

Company Drug

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Company Drug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

Company Drug

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.